Sandhill Capital Partners Raised Diplomat Pharmacy Com (DPLO) Holding; Ampliphi Biosciences (NYSEMKT:APHB) Shorts Increased By 163.75%

July 28, 2017 - By Vivian Currie

Ampliphi Biosciences Corporation (NYSEMKT:APHB) had an increase of 163.75% in short interest. APHB’s SI was 590,000 shares in July as released by FINRA. Its up 163.75% from 223,700 shares previously. With 420,200 avg volume, 1 days are for Ampliphi Biosciences Corporation (NYSEMKT:APHB)’s short sellers to cover APHB’s short positions. About 140,634 shares traded. Ampliphi Biosciences Corp (NYSEMKT:APHB) has declined 94.86% since July 28, 2016 and is downtrending. It has underperformed by 111.56% the S&P500.

Sandhill Capital Partners Llc increased Diplomat Pharmacy Inc Com (DPLO) stake by 14.24% reported in 2016Q4 SEC filing. Sandhill Capital Partners Llc acquired 52,679 shares as Diplomat Pharmacy Inc Com (DPLO)’s stock rose 20.96%. The Sandhill Capital Partners Llc holds 422,605 shares with $5.33 million value, up from 369,926 last quarter. Diplomat Pharmacy Inc Com now has $1.03 billion valuation. The stock rose 2.26% or $0.34 reaching $15.39 per share. About 475,753 shares traded. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 40.48% since July 28, 2016 and is downtrending. It has underperformed by 57.18% the S&P500.

Among 12 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. Diplomat Pharmacy had 21 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by Bank of America on Tuesday, June 7 with “Neutral”. On Wednesday, November 23 the stock rating was downgraded by Credit Suisse to “Underperform”. The firm earned “Market Perform” rating on Thursday, November 3 by Raymond James. The rating was initiated by UBS with “Buy” on Wednesday, October 21. The company was maintained on Tuesday, August 4 by Leerink Swann. The stock has “Market Perform” rating by Cowen & Co on Thursday, November 3. The company was downgraded on Thursday, November 3 by Leerink Swann. Mizuho maintained Diplomat Pharmacy Inc (NYSE:DPLO) rating on Wednesday, October 21. Mizuho has “Buy” rating and $44 target. Barclays Capital initiated Diplomat Pharmacy Inc (NYSE:DPLO) rating on Wednesday, January 6. Barclays Capital has “Overweight” rating and $41 target. Avondale downgraded the shares of DPLO in report on Thursday, November 3 to “Mkt Perform” rating.

Investors sentiment decreased to 0.94 in Q4 2016. Its down 0.88, from 1.82 in 2016Q3. It worsened, as 39 investors sold DPLO shares while 48 reduced holdings. 30 funds opened positions while 52 raised stakes. 42.49 million shares or 16.74% less from 51.03 million shares in 2016Q3 were reported. 33,061 are held by American Group. 3,485 are owned by Da Davidson And. Legal And General Gru Public Lc reported 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Moreover, Principal Fincl Gru Inc has 0.01% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 314,277 shares. Hsbc Hldg Public Limited reported 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Clearbridge Investments Limited Com holds 1.24 million shares or 0.02% of its portfolio. Fifth Third Fincl Bank reported 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Royal National Bank & Trust Of Canada reported 14,570 shares stake. Ameriprise Financial Inc owns 237,062 shares for 0% of their portfolio. Blackrock Gru Ltd holds 81,640 shares or 0% of its portfolio. Cambridge Investment Advsr owns 1.38 million shares. Menta Capital Ltd Liability Corp reported 11,377 shares. Friedberg Mngmt owns 0.13% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 21,950 shares. Paradigm Asset Mngmt Lc accumulated 23,000 shares. Rhumbline Advisers reported 0% stake.

AmpliPhi Biosciences Corporation is a biotechnology company. The company has market cap of $7.55 million. The Firm is focused on the discovery, development and commercialization of phage therapeutics. It currently has negative earnings. The Firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.